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reverse transcription-polymerase chain reaction from the pa-Glyoxalase I deficiency is associated with an unusual level of
tient’s mononuclear cells revealed no genetic mutation withinadvanced glycation end products in a hemodialysis patient.
the coding region of the glyoxalase I gene. Plasma d-lactateBackground. Advanced glycation of proteins and their at-
tendant advanced glycation end products (AGEs) contribute to level was also in the lower range (0.18  0.03 mg/dL) of the
the complications associated with diabetes mellitus or uremia. values measured in the other HD patients (0.27  0.09 mg/
Regulatory mechanisms of AGE formation in vivo remain dL) and normal subjects (0.35 0.12 mg/dL). The plasma levels
an issue of particular interest. We investigated a role of the of various compounds known to generate AGE precursors
glyoxalase detoxification system of precursor reactive carbonyl (glucose, lipids and ascorbic acid) were either normal or low.
compounds (RCOs) in the in vivo AGE formation. The surrogate markers for oxidative stress such as antioxidant
Methods. Plasma levels of AGEs [pentosidine and Nε-car- enzymes (glutathione peroxidases and superoxide dismutase)
boxymethyllysine (CML)], their RCO precursors, d-lactate and glutathione were all within the range observed in the other
(the final product resulting from the glyoxalase detoxification HD patients.
pathway), as well as of various compounds known to generate Conclusion. The unusually high levels of AGEs in this pa-
AGE precursors and surrogate markers for oxidative stress tient implicate a deficient glyoxalase detoxification of RCO
(antioxidant enzymes and glutathione), were measured in both precursors. The present clinical observation implicates, to our
hemodialysis (HD) patients and normal subjects. The activity knowledge for the first time, the glyoxalase detoxification sys-and protein expression of glyoxalase I, an enzyme essential for
tem and, in particular, glyoxalase in the actual level of AGEsthe detoxification of -oxoaldehydes, in red blood cells (RBC)
in a uremic patient.were also examined.
Results. In one 69-year-old lady who had been on hemodial-
ysis (HD) for three years and had suffered from recurrent
cardiovascular complications despite the absence of significant Advanced glycation end products (AGEs) contribute
risk factors, plasma levels of pentosidine (77.3  2.4 pmol/mg
to the development of complications associated with dia-protein) and CML (330.8  8.2 pmol/mg protein) were mark-
betes and uremia [1–4]. In uremic patients, their leveledly elevated as compared to other HD patients (N 20: 26.6
11.8 pmol/mg protein for pentosidine and 224.4 51.7 pmol/mg is dictated by the accumulation of precursor reactive
protein for CML). The plasma level of RCO precursors for carbonyl compounds (RCOs) [5], the so-called “uremic
pentosidine and CML was also higher in this patient than in
carbonyl stress” [6, 7].other HD patients. Further investigation disclosed a very low
Several mechanisms might account for RCO accumu-activity in RBC of glyoxalase I (1.5  0.4 mU/106 RBC), as
compared to other HD patients (3.9  0.6 mU/106 RBC) or lation in renal failure. Production of RCOs might be
normal subjects (4.0  0.6 mU/106 RBC). The glyoxalase I enhanced by the oxidative stress reported in uremic pa-
protein level, assessed in RBC by immunoblot analysis with a
tients [8]. This hypothesis is supported by the positivespecific antibody, was markedly lower than that observed in
correlations demonstrated in uremic serum betweenHD patients and normal subjects. The causes of this deficiency
remain unknown. Nucleotide sequencing of the products of pentosidine, an AGE compound, and markers of oxida-
tive stress such as dehydroascorbate [9], advanced oxida-
tion protein products (AOPP) [10] and superoxide dis-Key words: carbonyl compound, carbonyl stress, diabetes mellitus, ure-
mia, reactive carbonyl compounds, glyoxalase pathway. mutase (SOD) [11], as well as by the negative correlation
reported between serum pentosidine and glutathione
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Fig. 1. The glyoxalase detoxification pathway.
-Oxoaldehydes, such as methylglyoxal (gly-
oxal), react reversibly with the thiol group of
glutathione to be subsequently metabolized
by glyoxalases I and II into glutathione and
d-lactate (glycolate). Decrease in glutathione
levels or in glyoxalase activity might therefore
raise the level of a wide range of RCOs with
the attendant formation of AGEs.
both of which are derived from non-oxidative chemistry bles, cerebral infarction in July 1999, and unstable an-
gina. In January 2000, a coronary angiography showedand react with proteins to form AGEs.
a 90% stenosis of the left anterior descending coronaryAlternatively, RCOs might arise in uremia as a conse-
artery. As cardiovascular risk factor, she had smoked 5quence of an impaired detoxification. RCOs are metabo-
cigarettes a day for 10 years, but stopped 10 years earlier.lized by several enzymatic pathways, such as aldose re-
She had no family history of diabetes mellitus. Hyperten-ductase, aldehyde dehydrogenases, and the glyoxalase
sion developed after the onset of HD, but was easilypathway [14]. The latter pathway is believed to be of
controlled by nifedipine and doxazosin mesilate. Bodyparticular importance. It catalyzes the detoxification of
mass index was 16.4 (height 149 cm, weight 36.5 kg).-oxoaldehydes (RCOCHO), such as glyoxal, methylgly-
Biochemical data in December 1999 included fastingoxal and 3-deoxyglucosone, to corresponding aldonic
plasma glucose (102 mg/dL), serum total cholesterolacids [RCH(OH)COOH] (Fig. 1). To date, however,
(218 mg/dL), low-density-lipoprotein (129 mg/mL), tri-there is no evidence that the RCO detoxification mecha-
glyceride (189 mg/dL), high-density-lipoprotein (67 mg/nism might influence in vivo RCO and therefore serum
dL), lipoprotein (18.7 mg/dL), uric acid (7.1 mg/dL),AGE levels. The present clinical observation implicates,
ascorbic acid (1.5 g/mL), and C-reactive proteinto our knowledge for the first time, the glyoxalase detoxi-
(0.4 mg/dL). The red blood cell (RBC) count was 2.06 fication system and in particular glyoxalase, an essential
106/L [hemoglobulin (Hb) 7.2 g/dL, hematocrit (Hct)enzymatic element in the glyoxalase pathway, in the ac-
22.3%] and hemoglobulin A1C (HbA1c) was 5.4%. Thetual level of AGEs in a uremic patient.
discovery of strikingly elevated plasma levels of pentosi-
Case report dine initiated further investigations described hereafter.
A 69-year-old Japanese woman had been on regular
hemodialysis (HD) for three years. In 1985, at the age of
METHODS
55 years, she was told that her renal function was de-
Plasma samplescreased, probably due to chronic glomerulonephritis (no
renal biopsy). Blood pressure, and serum glucose and lipid Fresh heparinized plasma samples were obtained from
the index case, from 4 subjects (3 male) with a mean agelevels were normal. No drugs were given. Twelve years
later, in July 1997, atherosclerosis obliterans of the com- of 35.0  9.6 years and normal renal function, and from
20 non-diabetic HD patients (11 male) with a mean agemon iliac artery was discovered on angiography and
treated by a percutaneous transluminal angioplasty. Re- of 55.2  16.3 years. Informed consent was obtained
from all patients. Normal renal function was defined asnal function decreased progressively thereafter and HD
was started in May 1998. During the subsequent three a serum creatinine level below 1.0 mg/dL (88.4 mol/L)
and the absence of proteinuria by a negative Albustixyears, the patient suffered from several cardiovascular
complications, including arteriovenous (AV) fistula trou- (Bayer-Sankyo Co. Ltd., Tokyo, Japan). HD was per-
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formed in all investigated uremic patients with a modi- matography/mass spectrometry (GC/MS), as described
previously [18]. The CML and d4-CML standards [19]fied-cellulose membrane (surface area 1.0 to 2.0 m2) and
were gifts from Dr. John W. Baynes. The limit of detec-a dialysate containing 5.56 mmol/L glucose, 30 mmol/L
tion was 1.0 pmol of CML per mg of protein.bicarbonate and 8 mmol/L acetate. Protein concentra-
tion was measured by a Bio-Rad protein assay (Rich-
Antioxidant enzymes and glutathionemond, CA, USA) with human albumin as a standard.
The levels of Cu/Zn-superoxide dismutase and gluta-
In vitro incubation experiment thione peroxidase were measured in the plasma using
kits (Cu/Zn-superoxide dismutase; Amersham Pharma-Plasma samples were ultrafiltrated through a filter with
cia Biotech, Little Chalfont, UK; glutathione peroxidase;a 5000 D cut-off value (Ultrafree CL-LCC; Nihon Milli-
Oxis International, Portland, OR, USA).pore Ltd., Tokyo, Japan). Plasma ultrafiltrates (1.0 mL)
The concentration of glutathione in RBC was mea-were sterilized with a 0.22-m pore filter, fortified with
sured by a kit (BIOXYTECH GSH-400; Oxis Interna-essentially fatty acid-free grade bovine serum albumin
tional). This assay involves formation of thioethers be-(BSA; Sigma Chemical Co., St. Louis, MO, USA) to the
tween 4-chloro-1-methyl-7-trifluoromethyl-quinoliniumfinal concentration of 30 mg/mL, and subsequently incu-
methylsulfate and glutathione, and transformation of thebated under air in sealed sterile 1.5 mL plastic tubes at
thioether into a chromophoric thione, which has a maxi-37C for two and one weeks, followed by the determina-
mal absorbance wavelength at 400 nm.tion of pentosidine and CML contents, respectively. In
some experiments, incubation was performed in the pres- Glyoxalase I activity
ence of 10 mmol/L of either aminoguanidine (Tokyo
Red blood cells were obtained by centrifugation fromChemical Industry, Tokyo, Japan) [15] or ()-2-isopro-
heparinized blood samples, washed three times with sa-pylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide
line, and suspended in saline (10% hematocrit stock sus-(OPB-9195; developed by Fujii Memorial Research In-
pension).stitute, Otsuka Pharmaceutical, Ohtsu, Japan) [16].
The activity of glyoxalase I in RBC was assayed ac-
cording to the method by McLellan et al [20]. Briefly,Pentosidine and CML
the red blood cell suspension (10% hematocrit) was lysedPentosidine content was determined by high-perfor-
with 4 volumes of ice-cold distilled water. The membranemance liquid chromatographic (HPLC) assay as described
fragments were sedimented by centrifugation and lysates
previously [17]. In brief, the sample was lyophilized, hy- were assayed for glyoxalase I activity. Glyoxalase I activ-
drolyzed in 100 L of 6 N HCl for 16 hours at 110C ities are given in units/106 RBC, where 1 unit is the
under nitrogen, followed by neutralization with 100 L amount of enzyme required to catalyze the formation of
of 5 N NaOH and 200 L of 0.5 mol/L sodium phosphate 1 mol S-d-lactoylglutathione per minute.
buffer (pH 7.4), filtered through a 0.5 m filter, and di-
luted with phosphate-buffered saline (PBS). A sample Glyoxalase I protein level: Immunoblotting
(corresponding to 25 g of proteins) was injected into an The lysates from 2 106 RBC were separated by SDS-
HPLC system and fractionated on a C18 reverse-phase PAGE using a 4 to 20% acrylamide gel. Proteins were
column. The effluent was monitored at an excitation- transferred to a polyvinylidene difluoride membrane (Bio-
emission wavelength of 335/385 nm using a fluorescence Rad Laboratories, Hercules, CA, USA) electrophoretic-
detector (RF-10A: Shimadzu). Synthetic pentosidine ally. The membrane was blocked overnight at 4C with
was used to obtain a standard curve. Limits of detection PBS containing 0.05% Tween and 2% BSA, incubated
were 2 pmol of pentosidine per mg of protein. with rabbit anti-human glyoxalase I IgG (1.0g/mL) [21],
For quantitation of CML content, samples (100 L) (kindly provided by Dr. Sulabna Ranganathan, Depart-
were diluted with an equal volume of 0.2 mol/L sodium ment of Pharmacology, Fox Chase Cancer Center, PA,
borate (pH 9.1), followed by addition of 20 L 1 mol/L USA) for one hour at room temperature, and washed
NaBH4 in 0.1 N NaOH. Reduction was carried out for with PBS containing 0.05% Tween 20. The membrane
four hours at room temperature, and proteins were pre- was then incubated with 1:5,000 diluted alkaline phos-
cipitated by addition of an equal volume of 20% trichlo- phate conjugated goat anti-rabbit IgG (Cappel Labora-
roacetic acid and pelleted by centrifugation at 2,000  g tory, Durham, NC, USA) for one hour at room tempera-
for five minutes. The pellet was washed with 500 L ture, followed by washing and development with p-nitro
10% trichloroacetic acid. Heavy labeled internal stan- blue tetrazolium chloride and 5-bromo-4-chloro-3-indo-
dards (d4-CML) were added and the samples hydrolyzed lyl-phosphate solution (Bio-Rad Laboratories).
in 0.3 mL 6 N HCl at 110C for 16 hours. The hydrolysates
D-Lactatewere dried under a stream of nitrogen. CML content in
the hydrolysates was determined as its N,O-trifluoroa- d-Lactate was measured in plasma samples by the
method of Brandt et al [22]. This assay is based on thecetyl methyl esters by selected-ion monitoring gas chro-
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Fig. 2. Plasma pentosidine and Nε-carboxymethyllysine (CML) levels in normal and hemodialysis (HD) subjects. Pentosidine (A) and CML (B)
contents in acid hydrolysates of plasma from normal subjects (N  4), non-diabetic HD patients (N  20), and the index patient () were
determined by HPLC or GC/MS assay, respectively. Data are expressed as means  SD.
enzymatic oxidation of d-lactate with a specific d-lactate Statistical analysis
dehydrogenase coupled to reduction of nicotinamide Data are expressed as means  SD. The Mann-Whit-
adenine dinucleotide (NAD) with the spectrophoto- ney test was used for a statistical evaluation of significant
metric measurement of NADH at 340 nm. difference between HD patients (not including the index
patient) and normal healthy subjects. Correlation was
Genetic analysis for glyoxalase I gene assessed by linear regression analysis. A P value below
Heparinized peripheral blood samples were collected 0.05 was considered statistically significant.
from the index patient and two healthy volunteers. Mono-
nuclear cells were isolated from the blood by Ficoll cen-
RESULTStrifugation. RNA isolated from mononuclear cells by a
Elevated plasma levels of AGEs and theirkit (ISOGEN: Nippon Gene, Tokyo, Japan) were re-
precursor RCOsverse-transcribed with oligo(dT)12–18 primers with RNase
H-free reverse transcriptase (Superscript II: Gibco BRL, The patient’s plasma pentosidine level reached 77.3 
Gaithersburg, MD, USA). The coding region of glyox- 2.4 pmol/mg protein, a value that far exceeded those
alase I was then amplified by polymerase chain reaction observed in the HD (26.6  11.8 pmol/mg) or normal
(PCR) with primers, sense (5	-GTA GTG TGG GTG healthy (1.76  0.23 pmol/mg protein) subjects (Fig. 2A).
ACT CCT CCG TTC CTT GGG-3	) and antisense The plasma CML level reached 330.8  8.2 pmol/mg
(5	-TCC TTT CTT CTG AAA TCT CAA AGG AGA protein, a remarkably high value when compared with
ATT CTC-3	) with an initial denature at 94C for five other HD (224.4  51.7 pmol/mg protein) and normal
minutes, followed by 30 cycles of 94C for 30 seconds, (43.0  6.5 pmol/mg protein) subjects (Fig. 2B). The
60C for 30 seconds, and 72C for one minute. index patient’s elevated levels were documented on
The amplified products from the coding region of three different occasions.
glyoxalase I (648 bp) were subcloned into plasmids for To assess the levels of precursor RCOs accumulated
determination of their nucleotide sequences by ABI in the circulation, we incubated ultrafiltrated plasma for-
PRISM 377 DNA sequencer (Perkin Elmer Biosys- tified with BSA for two and one weeks, and measured
tems, Foster, CA, USA). Both strands of the cloned the in vitro generation of pentosidine and CML, respec-
tively. Generation of both pentosidine and CML wasproducts were sequenced in 20 clones from each subject.
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Fig. 3. Generation of pentosidine and CML upon incubation of plasma ultrafiltrates. Plasma ultrafiltrates (5000 D), obtained from normal
subjects (N  4), non-diabetic HD patients (N  6) and the index patient (), were fortified with BSA (final concentration: 30 mg/mL) and
incubated at 37C for one (CML) or two (pentosidine) weeks under air. Pentosidine (A) and CML (B) contents in acid hydrolysates were determined
by HPLC or GC/MS assay, respectively. Data are expressed as means  SD. NS, not significant.
much higher in this patient than in other HD patients or 71.5  25.7 ng/mL; erythrocyte Cu, Zn-SOD, 6.04 
0.65 ng/106 RBC).normal subjects (Fig. 3). The addition of aminoguanidine
or OPB-9195, both of which inhibit the carbonyl amine
Glyoxalase pathway for the detoxification ofreactions [16], inhibited pentosidine and CML genera-
RCO precursorstion during the incubation of plasma ultrafiltrates (data
not shown). These results demonstrate that the plasma The RBC level of glutathione, an essential element in
precursors of pentosidine and CML are indeed RCOs the glyoxalase pathway, reached 0.131  0.012 nmol/
and that their levels are remarkably higher in the index 106 RBC in the index patient, a value well within the
patient than in other HD patients and normal subjects. range observed in other HD patients (0.145 0.024 nmol/
106 RBC; Fig. 4A), as well as in normal subjects (0.141
Causes of elevated levels of RCOs 0.015 nmol/106 RBC). Glutathione levels expressed per
precursors of AGEs blood volume were similar in the index patient (0.30 
To understand why AGEs and AGE precursor RCO 0.03 mol/mL) and in HD patients (0.45  0.11 mol/
levels were so high in this patient, further biochemical mL) but significantly lower than in normal subjects (0.68
analyses were performed. As pointed out in the case 0.07 mol/mL) as a result of the concomitant anemia.
report, the levels of various compounds known to gener- The activity of the glyoxalase I enzyme, another key
ate AGE precursors such as glucose, triglycerides, and element of the glyoxalase pathway, was measured. It is of
ascorbic acid were either within normal limits or low. note that the glyoxalase I activity in RBC was markedly
lower in the index patient (1.5  0.4 mU/106 RBC) than
Oxidative stress in the other HD patients (3.9  0.6 mU/106 RBC) or
normal subjects (4.0 0.6 mU/106 RBC; Fig. 4B). SimilarThe plasma activities of glutathione peroxidase and
superoxide dismutases, two antioxidant enzymes, were results were obtained on three different days in the index
patient.used as an index of associated oxidative stress. Their
levels in the index patient (plasma glutathione perox- The protein level of glyoxalase I in RBC was deter-
mined by immunoblot analysis with a specific antibody.idase 14.9 g/mL; plasma Cu, Zn-SOD, 79.6 ng/mL; ery-
throcyte Cu, Zn-SOD, 6.10 ng/106 RBC) were similar to The level in the index patient was almost half of that
measured in other HD and normal subjects (Fig. 5).those measured in other HD patients (plasma glutathi-
one peroxidase 14.8 2.97 g/mL; plasma Cu, Zn-SOD, In agreement with the decreased glyoxalase I activity
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Fig. 4. Glutathione levels (A) and glyoxalase I activity (B) in RBC. (A) Glutathione concentrations in RBC from normal subjects (N  4), non-
diabetic HD patients (N  20) and the index patient (closed square) were determined by the spectrophotometric assay. (B) The red blood cell
lysates were obtained from normal subjects (N  4), non-diabetic HD patients (N  20) and the index patient (), and the glyoxalase I activities
were assayed. NS, not significant.
and its attendant impaired detoxification of RCOs, the RCO precursors of AGEs in uremic serum, the so-called
plasma level of D-lactate, a final product of the glyoxa- uremic carbonyl stress, and demonstrated that it played
lase pathway, measured in the index case (0.18 0.03 mg/ a critical role in determining serum AGE levels [5–7]. In
dL) was within the lower part of the range observed the present patient, we demonstrate that the markedly ele-
in other HD patients (0.27  0.09 mg/dL) and normal vated AGE levels are associated with a similarly raised
subjects (0.35  0.12 mg/dL; Fig. 6). carbonyl stress. Indeed, the AGE forming potential of
the index patient’s serum, taken as a marker of circulat-
Genetic analysis ing RCOs, is higher than those of other HD patients.
The nucleotide sequences of the coding region of gly- It remains to be seen whether the marked rise in RCOs
oxalase I were determined in the index patient. All nucle- observed in our patient is due to an enhanced production
otide sequences of the 20 cloned products of reverse or to a decreased removal as compared to other HD pa-
transcription-polymerase chain reaction (RT-PCR) were tients. Enhanced production appears unlikely in view of
completely identical to those reported for glyoxalase I. the normal serum levels of glucose and lipids, both pre-
No genetic mutation within the coding region of the cursors of RCOs. Although a recent study suggested that
glyoxalase I gene was thus identified in the index case. mitochondrial reactive oxygen species are involved in the
intracellular formation of methylglyoxal-derived AGEs
[23], an augmented RCO production due to an increasedDISCUSSION
oxidative stress is also unlikely, as markers of oxidativeThe present case report provides suggestive first evi-
stress such a glutathione peroxidase and superoxide dis-dence that AGE levels can be markedly influenced by
mutase were similar in the index case and in other HDthe activity of the detoxification systems clearing the
patients.RCO precursors of AGEs.
The alternative hypothesis of an impaired detoxifica-The plasma levels of two representative AGEs, pen-
tion is more attractive [6]. We have investigated onlytosidine and CML, were unusually elevated in our index
the glyoxalase pathway, which is believed to play anpatient. Interestingly, the correlation reported between
important role. Reduced glutathione contributes to thethese two species [18], extended to these very high levels
activity of this pathway. Methylglyoxal, for example, re-(Fig. 7A). This observation strongly suggests the pres-
acts reversibly with its thiol group and is subsequentlyence of an underlying common cause.
We have previously documented the accumulation of metabolized by glyoxalases I and II into glutathione and
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Fig. 6. Plasma D-lactate levels. d-Lactate concentrations in plasma
from normal subjects (N  4), non-diabetic HD patients (N  20) and
the index patient () were determined by the spectrophotometric assay.
NS, not significant.
of another gene regulating product. Nevertheless, nucle-
otide sequencing of the products of RT-PCR from mono-
nuclear cells of our patient revealed no genetic mutation
within the coding region of the glyoxalase I gene. TheFig. 5. Immunochemical detection of glyoxalase I in RBC. The cell
lysates from normal subjects (N  2), non-diabetic HD patients (N  possibility remains that some genetic mutation exists in
2) and the index patient were resolved by 4 to 20% SDS-PAGE, fol- the 5	 or 3	 region (promotor/enhancer region) of thelowed by immunoblotting with anti-glyoxalase I antibody (A). (B) Ra-
glyoxalase I gene or in another genomic region affectingtios of intensities of glyoxalase I level calculated by densitometry.
the stability or expression of glyoxalase I mRNA. At any
rate, the reproducibility of the observed abnormalities in
our index case clearly points to a real phenomenon.
d-lactate (Fig. 1). Decreased levels of glutathione might The present data demonstrate that a lowered glyox-
therefore raise the serum level of a wide range of RCOs. alase I activity is accompanied in a uremic subject by an
This was not the case, since the RBC glutathione level augmented level of RCOs and of AGEs. It remains to
was similar in our patient and in the other HD patients. be seen whether the glyoxalase pathway regulates AGE
The most striking observation in our patient is the level in uremia. The observation that neither pentosidine
markedly reduced level of glyoxalase I activity. This re- nor CML levels are correlated with the level of glyoxa-
duction is confirmed by the immunoblot analysis of pro- lase I activity usually present in HD patients, that is,
tein levels of glyoxalase I in RBC and fits with the low outside our patient, suggests that this is not the case
serum level of d-lactate. This data suggest a causal link for this enzyme. The possibility that other detoxification
between glyoxalase I activity and serum concentration steps limit the clearance of RCO precursors of AGEs is
of the two AGEs. yet to be explored.
The causes of a reduced level of glyoxalase I in our Nevertheless, the evidence that unusually low levels
patient remain to be determined. It might be suggested of glyoxalase I are associated with strikingly elevated
that our case is only an outlier in a normal distribution levels of AGEs and RCO precursors raises the possibility
of activity. While this possibility cannot be ruled out, it that maneuvers augmenting glyoxalase I activity might
does not fit with the observation that the index case is lower RCO and AGE levels and thus opens new thera-
clearly outside the population of HD patients in the graphs peutic avenues.
relating glyoxalase I and either pentosidine (Fig. 7B) or Our index patient’s evolution was marred by multiple
CML (Fig. 7C). Alternatively, the enzyme level may be cardiovascular complications despite the virtual absence
of predisposing factors, except for a ten-year mild expo-abnormally low as a consequence of a mutated gene or
Miyata et al: AGEs in a glyoxalase deficient patient2358
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APPENDIX
Abbreviations used in this paper are: AGE, advanced glycation end
product; AOPP, advanced oxidation protein products; BSA, bovine
serum albumin; CML, Nε-carboxymethyllysine; HD, hemodialysis; HPLC,
high-pressure liquid chromatography; RBC, red blood cell; RCO,
reactive carbonyl compound; RCOCHO, -oxoaldehydes; RCH(OH)-
COOH, aldonic acids; RT-PCR, reverse transcription-polymerase
chain reaction; SOD, superoxide dismutase.
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